Back to results
US 8,133,688 B2Granted
Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
AssigneeCanimguide Therapeutics AB
InventorsLeif Hakansson, Birgitta Clinchy
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCanimguide Therapeutics AB
InventorsLeif Hakansson, Birgitta Clinchy
Estimating the term…
The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.
A method of indicating the presence of a factor in a biological sample of a rheumatoid arthritis patient that inhibits the binding of an antibody or fragment thereof, which is specific for denatured human serum albumin comprising:
A method of indicating the presence of a factor in a sample of human serum from a rheumatoid arthritis patient that inhibits the binding of an antibody or fragment thereof, which is specific for denatured human serum albumin comprising:
A method of indicating the presence of a factor in a biological sample of a rheumatoid arthritis patient that inhibits the binding of an antibody or fragment thereof, which is specific for denatured human serum albumin, comprising:
A method of indicating the presence of a factor in a sample of human serum from a rheumatoid arthritis patient that inhibits the binding of an antibody or fragment thereof, which is specific for denatured human serum albumin comprising:
Dependencies are inferred from the claim text.